StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > New Partnership with Teen Cancer America

<< Previous

Bullboard Posts

Next >>

Comment by RelevantStockon Nov 11, 2021 2:57pm

119 Views

Post# 34116371

RE:New Partnership with Teen Cancer America

Awesome find, thanks Jonny. If we reach 0.35 in the next days we could start a daily reversal. I am neutral on the earnings, but CA revenue combined with unexpected covid testing revenu could surprise. Bolta

Jonnyboy85 wrote:
StageZero and TCA plan several initiatives, including:

A combined educational campaign aimed at generating awareness around the challenges faced by adolescents and young adults with cancer and the need to improve screening and treatment.

Dissemination of TCA's soon to be published health economic research that reveals the true cost of cancer for young people, health systems, and society.

Stage Zero's clinical studies to validate their Aristotle® technology in the early detection of testicular, brain, and colorectal cancers in adolescents and young adults.